SAN FRANCISCO, June 4 2026
Chai Discovery has announced a strategic license agreement with Pfizer that will enable the global biopharmaceutical company to deploy Chai’s advanced artificial intelligence drug discovery platform across its research organization. The collaboration marks a significant step forward in the adoption of generative AI for biologics discovery, providing Pfizer with early access to Chai’s next-generation Chai-3 model and a customized AI system trained using Pfizer’s proprietary scientific data. The agreement highlights the growing role of AI-driven drug discovery technologies in accelerating the development of new therapeutics and addressing complex biological targets that have historically proven difficult to treat.
Pfizer Gains Access to Chai-3 and Custom AI Models
Under the terms of the agreement, Pfizer will integrate Chai Discovery’s platform into its existing drug discovery infrastructure, allowing researchers to leverage advanced AI capabilities to design and optimize therapeutic molecules. The partnership grants Pfizer early access to Chai-3, the company’s most advanced AI model for molecular engineering, along with a custom-built model tailored specifically to Pfizer’s scientific workflows and internal datasets.
According to Chai Discovery, the collaboration is designed to combine Pfizer’s extensive expertise in pharmaceutical research with Chai’s cutting-edge AI technologies. By applying machine learning models capable of predicting and reprogramming molecular interactions, researchers aim to accelerate the identification of promising biologics candidates while reducing the time and resources traditionally required for early-stage drug discovery. The partnership reflects a broader industry trend in which major pharmaceutical companies are increasingly investing in AI platforms to improve research productivity and enhance innovation pipelines.
Chai-3 Demonstrates Significant Advances in Antibody Design
Advertisement
A key component of the agreement is Pfizer’s access to Chai-3, a previously undisclosed AI model that represents the latest evolution of Chai Discovery’s molecular design platform. The company reports that Chai-3 delivers substantial improvements in AI-driven antibody engineering, achieving approximately double the success rate of its predecessor while generating antibodies capable of meeting stringent therapeutic standards.
According to Chai Discovery, the collaboration is designed to combine Pfizer’s extensive expertise in pharmaceutical research with Chai’s cutting-edge AI technologies. By applying machine learning models capable of predicting and reprogramming molecular interactions, researchers aim to accelerate the identification of promising biologics candidates while reducing the time and resources traditionally required for early-stage drug discovery. The partnership reflects a broader industry trend in which major pharmaceutical companies are increasingly investing in AI platforms to improve research productivity and enhance innovation pipelines.
Chai-3 Demonstrates Significant Advances in Antibody Design
A key component of the agreement is Pfizer’s access to Chai-3, a previously undisclosed AI model that represents the latest evolution of Chai Discovery’s molecular design platform. The company reports that Chai-3 delivers substantial improvements in AI-driven antibody engineering, achieving approximately double the success rate of its predecessor while generating antibodies capable of meeting stringent therapeutic standards.
The model is designed to enhance the discovery of molecules targeting challenging disease mechanisms, including hard-to-drug proteins and complex biological pathways. Chai-3 also supports the development of multispecific antibodies, enabling researchers to engineer molecules capable of interacting with multiple targets simultaneously. These capabilities could significantly expand the range of diseases that can be addressed through biologic medicines while improving the efficiency of therapeutic development programs.
The new model builds on the success of Chai-2, released in 2025, which became the first zero-shot antibody design platform to achieve double-digit experimental hit rates while generating molecules with drug-like characteristics. Chai Discovery reported that Chai-2 improved molecular discovery efficiency by approximately 100-fold compared with previous computational approaches, allowing projects that once required months of laboratory experimentation to be completed within weeks.
Growing Adoption of AI Across Pharmaceutical Research
The Pfizer agreement represents another milestone in the rapid adoption of frontier AI technologies across the pharmaceutical industry. As AI models become increasingly capable of predicting biological structure and function, leading drug developers are seeking partnerships that can shorten development timelines, reduce research costs, and improve success rates in therapeutic discovery.
Chai Discovery’s platform is specifically designed to generate novel biomolecules from scratch and help scientists pursue previously inaccessible therapeutic targets. By combining advanced AI reasoning with pharmaceutical expertise, the company aims to transform drug development from a largely experimental process into a more predictable engineering discipline.
Founded in 2024 and headquartered in San Francisco, Chai Discovery has attracted significant attention from investors and industry leaders. The company is backed by prominent technology and healthcare investors and continues to position itself at the forefront of AI-powered biotechnology innovation. The new agreement with Pfizer underscores the increasing confidence that major pharmaceutical companies have in AI as a strategic tool for discovering the next generation of medicines and addressing some of the most challenging diseases facing patients worldwide.
Source: Chai Discovery, Pfizer press release
